Trial Outcomes & Findings for Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities (NCT NCT02621476)
NCT ID: NCT02621476
Last Updated: 2023-08-08
Results Overview
users of the mail order pharmacy service - if they utilized the mail order system to deliver medications anytime in the 12 months following the date of outreach into the intervention
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
63012 participants
Primary outcome timeframe
12 months following the date of outreach into the intervention
Results posted on
2023-08-08
Participant Flow
Participant milestones
| Measure |
Standardized Intervention
Participants in the standardized intervention arm received outreach encouraging mail order pharmacy use.
|
Control
Participants in the control arm received usual care.
|
|---|---|---|
|
Overall Study
STARTED
|
31493
|
31519
|
|
Overall Study
COMPLETED
|
26342
|
26404
|
|
Overall Study
NOT COMPLETED
|
5151
|
5115
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
This measure applies only to KPNC and KPHI participants.
Baseline characteristics by cohort
| Measure |
Standardized Intervention
n=31493 Participants
Participants in the standardized intervention arm received outreach encouraging mail order pharmacy use.
|
Control
n=31519 Participants
Participants in the control arm received usual care.
|
Total
n=63012 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
<20
|
13 Participants
n=31493 Participants
|
16 Participants
n=31519 Participants
|
29 Participants
n=63012 Participants
|
|
Age, Customized
20-29
|
235 Participants
n=31493 Participants
|
232 Participants
n=31519 Participants
|
467 Participants
n=63012 Participants
|
|
Age, Customized
30-39
|
1323 Participants
n=31493 Participants
|
1261 Participants
n=31519 Participants
|
2584 Participants
n=63012 Participants
|
|
Age, Customized
40-49
|
4429 Participants
n=31493 Participants
|
4692 Participants
n=31519 Participants
|
9121 Participants
n=63012 Participants
|
|
Age, Customized
50-59
|
9198 Participants
n=31493 Participants
|
9406 Participants
n=31519 Participants
|
18604 Participants
n=63012 Participants
|
|
Age, Customized
60-69
|
9132 Participants
n=31493 Participants
|
9028 Participants
n=31519 Participants
|
18160 Participants
n=63012 Participants
|
|
Age, Customized
70-79
|
5092 Participants
n=31493 Participants
|
4981 Participants
n=31519 Participants
|
10073 Participants
n=63012 Participants
|
|
Age, Customized
80-89
|
1890 Participants
n=31493 Participants
|
1743 Participants
n=31519 Participants
|
3633 Participants
n=63012 Participants
|
|
Age, Customized
>89
|
181 Participants
n=31493 Participants
|
160 Participants
n=31519 Participants
|
341 Participants
n=63012 Participants
|
|
Sex: Female, Male
Female
|
14204 Participants
n=31493 Participants
|
14184 Participants
n=31519 Participants
|
28388 Participants
n=63012 Participants
|
|
Sex: Female, Male
Male
|
17289 Participants
n=31493 Participants
|
17335 Participants
n=31519 Participants
|
34624 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
7811 Participants
n=31493 Participants
|
7815 Participants
n=31519 Participants
|
15626 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
Black
|
3867 Participants
n=31493 Participants
|
3872 Participants
n=31519 Participants
|
7739 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
HI/PI
|
1315 Participants
n=31493 Participants
|
1314 Participants
n=31519 Participants
|
2629 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
Asian
|
5900 Participants
n=31493 Participants
|
5595 Participants
n=31519 Participants
|
11495 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
Native American
|
123 Participants
n=31493 Participants
|
186 Participants
n=31519 Participants
|
309 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
White
|
7500 Participants
n=31493 Participants
|
7822 Participants
n=31519 Participants
|
15322 Participants
n=63012 Participants
|
|
Race/Ethnicity, Customized
Missing
|
4977 Participants
n=31493 Participants
|
4915 Participants
n=31519 Participants
|
9892 Participants
n=63012 Participants
|
|
Region of Enrollment
United States
|
31493 participants
n=31493 Participants
|
31519 participants
n=31519 Participants
|
63012 participants
n=63012 Participants
|
|
Has Mail Order Incentive
|
20321 Participants
n=31493 Participants
|
20007 Participants
n=31519 Participants
|
40328 Participants
n=63012 Participants
|
|
Has Secure Messaging
|
15009 Participants
n=26099 Participants • This measure applies only to KPNC and KPHI participants.
|
15019 Participants
n=26125 Participants • This measure applies only to KPNC and KPHI participants.
|
30028 Participants
n=52224 Participants • This measure applies only to KPNC and KPHI participants.
|
|
Had Oral Diabetes Mellitus (DM) Drug Fill
|
25370 Participants
n=31493 Participants
|
25400 Participants
n=31519 Participants
|
50770 Participants
n=63012 Participants
|
|
Had Oral Dyslipidemia (DL) Drug Fill
|
25924 Participants
n=31493 Participants
|
25939 Participants
n=31519 Participants
|
51863 Participants
n=63012 Participants
|
|
Had Oral Hypertension (HT) Drug Fill
|
26785 Participants
n=31493 Participants
|
26891 Participants
n=31519 Participants
|
53676 Participants
n=63012 Participants
|
|
Total Number of Oral Cardiovascular Disease (CVD) Drug Fills
|
13.5 Oral CVD drug fills
STANDARD_DEVIATION 10.2 • n=31493 Participants
|
13.5 Oral CVD drug fills
STANDARD_DEVIATION 10.2 • n=31519 Participants
|
13.5 Oral CVD drug fills
STANDARD_DEVIATION 10.2 • n=63012 Participants
|
|
Total Number of Oral HT Drug Fills
|
7.3 Oral HT drug fills
STANDARD_DEVIATION 6.4 • n=31493 Participants
|
7.4 Oral HT drug fills
STANDARD_DEVIATION 6.5 • n=31519 Participants
|
7.4 Oral HT drug fills
STANDARD_DEVIATION 6.5 • n=63012 Participants
|
|
Total Number of Oral DM Drug Fills
|
5.3 Oral DM drug fills
STANDARD_DEVIATION 4.2 • n=31493 Participants
|
5.3 Oral DM drug fills
STANDARD_DEVIATION 4.1 • n=31519 Participants
|
5.3 Oral DM drug fills
STANDARD_DEVIATION 4.2 • n=63012 Participants
|
|
# of classes of Oral CVD Drugs
|
3.5 Classes of Oral CVD drug fills
STANDARD_DEVIATION 1.6 • n=31493 Participants
|
3.5 Classes of Oral CVD drug fills
STANDARD_DEVIATION 1.6 • n=31519 Participants
|
3.5 Classes of Oral CVD drug fills
STANDARD_DEVIATION 1.6 • n=63012 Participants
|
|
# of drug classes poorly adherent to
|
1.7 Drug classes poorly adhered to
STANDARD_DEVIATION 1.0 • n=31493 Participants
|
1.7 Drug classes poorly adhered to
STANDARD_DEVIATION 1.0 • n=31519 Participants
|
1.7 Drug classes poorly adhered to
STANDARD_DEVIATION 1.0 • n=63012 Participants
|
|
% of Oral CVD drug classes poorly adherent to
|
57.6 % of Oral CVD drug classes poorly adhere
STANDARD_DEVIATION 31 • n=31493 Participants
|
57.6 % of Oral CVD drug classes poorly adhere
STANDARD_DEVIATION 31 • n=31519 Participants
|
57.6 % of Oral CVD drug classes poorly adhere
STANDARD_DEVIATION 31 • n=63012 Participants
|
|
Diabetes Identification
One Inpatient Diagnosis
|
100 Participants
n=31493 Participants
|
79 Participants
n=31519 Participants
|
179 Participants
n=63012 Participants
|
|
Diabetes Identification
One Prescription Fill
|
15802 Participants
n=31493 Participants
|
15760 Participants
n=31519 Participants
|
31562 Participants
n=63012 Participants
|
|
Diabetes Identification
Two Outpatient Diagnosis
|
15591 Participants
n=31493 Participants
|
15680 Participants
n=31519 Participants
|
31271 Participants
n=63012 Participants
|
PRIMARY outcome
Timeframe: 12 months following the date of outreach into the interventionusers of the mail order pharmacy service - if they utilized the mail order system to deliver medications anytime in the 12 months following the date of outreach into the intervention
Outcome measures
| Measure |
Standardized Intervention
n=23642 Participants
Participants in the standardized intervention arm received outreach encouraging mail order pharmacy use.
|
Control
n=26404 Participants
Participants in the control arm received usual care.
|
|---|---|---|
|
Percent of Participants Using Mail Order Pharmacy (MOP) After Intervention
|
10.6 percentage of participants
Interval 10.3 to 11.0
|
9.3 percentage of participants
Interval 8.9 to 9.7
|
Adverse Events
Standardized Intervention
Serious events: 0 serious events
Other events: 0 other events
Deaths: 599 deaths
Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 582 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Julie Schmittdiel, PhD, MA
Kaiser Permanente Northern California
Phone: 5108913872
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place